Clinicians should be cognizant of the symptoms and risk factors associated with pulmonary hypertension (PH). While known PH poses significant therapeutic challenges, occult PH carries the added potential for unanticipated complications when treating concurrent medical illnesses. PH may occur with underlying medical conditions and risk factors or may occur de novo as idiopathic pulmonary arterial hypertension (IPAH). Symptoms of PH are frequently attributed to more common conditions, and their nonspecific nature and insidious onset may lead to delay in presentation, evaluation, and diagnosis. Initial symptoms are dyspnea, fatigue, chest pain, and palpitations. Lower extremity edema, presyncope, and syncope are symptoms of more advanced disease. Thorough evaluation of symptoms and identification of patients with risk factors for PH are critical in making a timely diagnosis. History and physical examination can identify patients with suspected PH. Further testing is necessary for definitive diagnosis, classification, assessment of severity, and guiding therapeutic decisions.
Abenhaim L., Moride Y., Brenot F., et al. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group. N Engl J Med.1996;335:609-616.
2.
Hyduk A., Croft JB, Ayala C., Zheng K., Zheng ZJ, Mensah GAPulmonary hypertension surveillance—United States, 1980-2002. MMWR Surveill Summ.2005;54:1-28.
3.
Rich S., Dantzker DR, Ayres SM, et al. Primary pulmonary hypertension: a national prospective study . Ann Intern Med.1987;107:216-223.
4.
Rich S.Primary Pulmonary Hypertension: Executive Summary from the World Symposium on Primary Pulmonary Hypertension. Evian, France: World Health Organization; 1998.
5.
Simonneau G. , Galie N., Rubin LJ, et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol.2004;43(suppl):5-12.
6.
Deng Z., Morse JH, Slager SL, et al. Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. Am J Hum Genet.2000;67:737-744.
7.
Lane KB, Machado RD, Pauciulo MW, et al. Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension. International PPH Consortium. Nat Genet.2000;26: 81-84.
8.
Machado RD, Pauciulo MW, Thomson JR, et al. BMPR2 haploinsufficiency as the inherited molecular mechanism for primary pulmonary hypertension. Am J Hum Genet.2001;68:92-102.
9.
Loyd JE, Butler MG, Foroud TM, Conneally PM, Phillips JA III, Newman JHGenetic anticipation and abnormal gender ratio at birth in familial primary pulmonary hypertension. Am J Respir Crit Care Med.1995; 152:93-97.
10.
Newman JH, Wheeler L., Lane KB, et al. Mutation in the gene for bone morphogenetic protein receptor II as a cause of primary pulmonary hypertension in a large kindred. N Engl J Med.2001;345:319-324.
11.
Newman JH, Trembath RC, Morse JA, et al. Genetic basis of pulmonary arterial hypertension: current understanding and future directions. J Am Coll Cardiol.2004; 43(Suppl S):33S-39S.
12.
McGoon M., Gutterman D., Steen V., et al. Screening, early detection, and diagnosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest.2004;126(Suppl):14S-34S.
13.
Barst RJ, McGoon M., Torbicki A., et al. Diagnosis and differential assessment of pulmonary arterial hypertension. J Am Coll Cardiol.2004;43(Suppl S):40S-47S.
14.
Koh ET, Lee P., Gladman DD, Abu-Shakra M.Pulmonary hypertension in systemic sclerosis: an analysis of 17 patients. Br J Rheumatol.1996;35:989-993.
15.
Ungerer RG, Tashkin DP, Furst D., et al. Prevalence and clinical correlates of pulmonary arterial hypertension in progressive systemic sclerosis. Am J Med.1983;75:65-74.
16.
Hadengue A. , Benhayoun MK, Lebrec D., Benhamou JPPulmonary hypertension complicating portal hypertension: prevalence and relation to splanchnic hemodynamics. Gastroenterology. 1991;100:520-528.
17.
McDonnell PJ , Toye PA, Hutchins GMPrimary pulmonary hypertension and cirrhosis: are they related?Am Rev Respir Dis.1983 ;127:437-441.
18.
Castro M., Krowka MJ, Schroeder DR, et al. Frequency and clinical implications of increased pulmonary artery pressures in liver transplant patients. Mayo Clin Proc.1996;71:543-551.
Colle IO, Moreau R., Godinho E., et al. Diagnosis of portopulmonary hypertension in candidates for liver transplantation: a prospective study. Hepatology. 2003;37: 401-409.
21.
Krowka MJ, Mandell MS, Ramsay MA, et al. Hepatopulmonary syndrome and portopulmonary hypertension: a report of the multicenter liver transplant database. Liver Transpl.2004;10:174-182.
22.
UNOS. Organ Distribution: Allocation of Thoracic Organs. Organ Procurement and Transplant Network Policies . Richmond, VA: United Network for Organ Sharing; 2005: 3.7.1-3.7.17.
23.
Maurer JR, Frost AE, Estenne M., Higenbottam T., Glanville ARInternational guidelines for the selection of lung transplant candidates. International Society for Heart and Lung Transplantation, American Thoracic Society, American Society of Transplant Physicians, European Respiratory Society . Transplantation. 1998;66:951-956.
24.
Orens JB, Estenne M., Arcasoy S., et al. International guidelines for the selection of lung transplant candidates: 2006 update—a consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant.2006;25:745-755.
25.
Gorlitzer M. , Ankersmit J., Fiegl N., et al. Is the transpulmonary pressure gradient a predictor for mortality after orthotopic cardiac transplantation?Transpl Int.2005; 18:390-395.
26.
Murali S., Kormos RL, Uretsky BF, et al. Preoperative pulmonary hemodynamics and early mortality after orthotopic cardiac transplantation: the Pittsburgh experience. Am Heart J.1993;126:896-904.
27.
Tenderich G. , Koerner MM, Stuettgen B., et al. Pre-existing elevated pulmonary vascular resistance: long-term hemodynamic follow-up and outcome of recipients after orthotopic heart transplantation. J Cardiovasc Surg (Torino) . 2000;41: 215-219.
28.
Pengo V., LensingAW, Prins MH, et al. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med.2004;350:2257-2264.
29.
Ahearn GS, Tapson VF, Rebeiz A., Greenfield JC Jr.Electrocardiography to define clinical status in primary pulmonary hypertension and pulmonary arterial hypertension secondary to collagen vascular disease. Chest. 2002; 122:524-527.
Filipek MS, Gosselin MVMultidetector pulmonary CT angiography: advances in the evaluation of pulmonary arterial diseases. Semin Ultrasound CT MR. 2004;25: 83-98.
32.
Doyle RL, McCrory D., Channick RN, Simonneau G., Conte J.Surgical treatments/interventions for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest.2004; 126(Suppl): 63S-71S.
33.
Ryan KL, Fedullo PF, Davis GB, Vasquez TE, Moser KMPerfusion scan findings understate the severity of angiographic and hemodynamic compromise in chronic thromboembolic pulmonary hypertension. Chest. 1988; 93:1180-1185.
34.
Marvisi M., Brianti M., Marani G., Del Borello R., Bortesi ML, Guariglia A.Hyperthyroidism and pulmonary hypertension. Respir Med.2002;96:215-220.
35.
Chu JW, Kao PN, Faul JL, Doyle RLHigh prevalence of autoimmune thyroid disease in pulmonary arterial hypertension . Chest.2002;122:1668-1673.
36.
Leuchte HH, Holzapfel M., Baumgartner RA, Neurohr C., Vogeser M., Behr J.Characterization of brain natriuretic peptide in long-term follow-up of pulmonary arterial hypertension. Chest. 2005;128:2368-2374.
37.
Fijalkowska A., Kurzyna M., Torbicki A., et al. Serum N-terminal brain natriuretic peptide as a prognostic parameter in patients with pulmonary hypertension . Chest. 2006; 129:1313-1321.
38.
Rafanan AL, Golish JA, Dinner DS, Hague LK, Arroliga ACNocturnal hypoxemia is common in primary pulmonary hypertension. Chest. 2001;120:894-899.
39.
Atwood CW Jr, McCrory D., Garcia JG, Abman SH, Ahearn GSPulmonary artery hypertension and sleep-disordered breathing: ACCP evidence-based clinical practice guidelines. Chest.2004;126(Suppl):72S-77S.
40.
Miyamoto S., Nagaya N., Satoh T., et al. Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension: comparison with cardiopulmonary exercise testing. Am J Respir Crit Care Med.2000;161(Pt 1):487-492.
41.
D'Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension: results from a national prospective registry. Ann Intern Med.1991;115:343-349.
42.
Badesch DB, Abman SH, Ahearn GS, et al. Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest.2004; 126(Suppl):35S-62S.
43.
Rich S., Kaufmann E., Levy PSThe effect of high doses of calcium channel blockers on survival in primary pulmonary hypertension. N Engl J Med.1992 ;327:76-81.
44.
Raffy O., Azarian R., Brenot F., et al. Clinical significance of the pulmonary vasodilator response during short-term infusion of prostacyclin in primary pulmonary hypertension . Circulation. 1996;93:484-488.
45.
Sitbon O., Humbert M., Jais X., et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation. 2005;111:3105-3111.
46.
McLaughlin VV, Genthner DE, Panella MM, Rich S.Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension . N Engl J Med.1998;338:273-277. 47. Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. Primary Pulmonary Hypertension Study Group. N Engl J Med.1996 ;334:296-302.
47.
Krasuski RA , Wang A., Harrison JK, Tapson VF, Bashore TMThe response to inhaled nitric oxide in patients with pulmonary artery hypertension is not masked by baseline vasodilator use . Am Heart J.2005;150:725-728.
48.
Sitbon O., Humbert M., Jagot JL, et al. Inhaled nitric oxide as a screening agent for safely identifying responders to oral calcium channel blockers in primary pulmonary hypertension . Eur Respir J. 1998;12:265-270.
49.
Sitbon O., Brenot F., Denjean A., et al. Inhaled nitric oxide as a screening vasodilator agent in primary pulmonary hypertension. A dose-response study and comparison with prostacyclin . Am J Respir Crit Care Med.1995;151 (Pt 1):384-389.
50.
Hoeper MM, Olschewski H., Ghofrani HA, et al. A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension. German PPH Study Group. J Am Coll Cardiol.2000;35:176-182.
51.
Opitz CF, Wensel R., Bettmann M., et al. Assessment of the vasodilator response in primary pulmonary hypertension. Comparing prostacyclin and iloprost administered by either infusion or inhalation. Eur Heart J.2003; 24:356-365.
52.
Nootens M., Schrader B., Kaufmann E., Vestal R., Long W., Rich S.Comparative acute effects of adenosine and prostacyclin in primary pulmonary hypertension. Chest.1995;107:54-57.
53.
Paciocco G. , Martinez FJ, Bossone E., Pielsticker E., Gillespie B., Rubenfire M.Oxygen desaturation on the six-minute walk test and mortality in untreated primary pulmonary hypertension. Eur Respir J. 2001;17: 647-652.
54.
Leuchte HH, Holzapfel M., Baumgartner RA, et al. Clinical significance of brain natriuretic peptide in primary pulmonary hypertension. J Am Coll Cardiol.2004; 43:764-770.
